KRAS and ovarian neoplasm: Two concurrent somatic mutations in two different genes were identified in 15.2% (12/79) of advanced ovarian tumors, and 11.0% of patients with HGSOC (7/64): #145, TP53(p.R249S)/FBXW7(p.R393*); #274, KRAS(p.G12D)/FBXW7(p.V409V); #275, TP53(p.R248Q)/APC(p.T1438Kfs*36); #343, KRAS(p.G12D)/PTEN(p.R233*); #359, TP53(p.Q331Rfs*14)/PIK3CA(p.H1047L); #406, TP53(IVS4+5G>A)/KRAS(p.G12C); and #538, TP53(p.C275F)/PTEN(p.S226Ifs*28) (Figure 3).